Clinical Trials
21 trialsMinitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens
University of Liege
Physical Therapy in Patients Undergoing Allo-HSCT With cGVHD
University of Seville
VICTORY
Melbourne Health
A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.
First Affiliated Hospital of Zhejiang University
TCDαβ/CD45RA Haploidentical Transplantation in Children With Leukemia
Shanghai Children's Medical Center
CY25
National Research Center for Hematology, Russia
GVHD Prophylaxis With Methotrexate in Haploidentical HCT Using Posttransplant Cyclophosphamide
University of Sao Paulo General Hospital
Chemotherapy and DLI for Prevention of Second Relapse in Patients With Relapsed Acute Leukemia After Allotransplant
Peking University People's Hospital
ToTem
University College, London
ATG/PTCy
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
ProT4
University College, London
Prophylactic Donor Lymphocyte Infusion After Allo-PBSCT for Patients With Very High-risk Hematologic Malignancies
Chinese PLA General Hospital
Interferon α for the Therapy of Minimal Residual Disease
Peking University People's Hospital
BioUV2017
Medical University of Graz
Maraviroc-Based GVHD Prophylaxis in HLA-Unrelated and HLA-Mismatched Related Transplantation
Affiliated Hospital to Academy of Military Medical Sciences
Open-Label Study Designed to Evaluate the Safety and Preliminary Efficacy of ApoCell for the Prevention of Acute GvHD
Hadassah Medical Organization
Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors
Ann & Robert H Lurie Children's Hospital of Chicago
Antithymocyte Globulin and Cyclosporine in Preventing Graft-Versus-Host Disease in Patients Undergoing Chemotherapy With or Without Radiation Therapy Followed By Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
National Cancer Institute (NCI)
Early Diagnosis of Aspergillosis in Patients at High Risk of Fungal Infection Caused by Treatment for Hematologic Cancer or Other Disease
National Cancer Institute (NCI)
T&B Depletion Non Malignant
Bambino Gesù Hospital and Research Institute
Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders
National Cancer Institute (NCI)